Core Viewpoint - The stock of药捷安康-B (02617) has experienced a significant decline, dropping over 77% from its peak, indicating volatility and potential concerns in the market [1] Company Overview -药捷安康 was listed on the Hong Kong Stock Exchange on June 23, with an initial offering price of 13.15 HKD and a total market capitalization of approximately 5.2 billion HKD at the time of listing [1] - The total share capital is about 397 million shares, with only around 549 million shares available for trading in the market, indicating a limited float [1] Market Activity - As of the latest report, the stock price fell to 150.4 HKD, with a trading volume of 602 million HKD and a total market capitalization of 59.693 billion HKD [1] - The stock was included in several indices, including the Hang Seng Innovation Drug Index and the Guozhen Hong Kong Stock Connect Innovation Drug Index, which may have influenced its trading dynamics [1] Index Inclusion Impact - The initial weight of药捷安康 in the indices was approximately 2.63%, leading to an estimated passive allocation of over 600 million HKD from related index funds, contributing to the stock's price volatility [1]
药捷安康-B尾盘跌近18% 较周二高点已跌超77% 总市值已不足600亿港元